High-grade Gliomas

CONTINUUM Lifelong Learning in Neurology

Volumn 23, Issue 6, Neuro-oncology, 2017, Pages 1548-1563

  Nayak, Lakshmi ^a   Reardon, David A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; LOMUSTINE; MOLECULAR MARKER; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL FEATURE; CLINICAL OUTCOME; GLIOBLASTOMA; GLIOMA; HUMAN; MOLECULARLY TARGETED THERAPY; OLIGODENDROGLIOMA; OVERALL SURVIVAL; REVIEW; TREATMENT RESPONSE; MULTIMODALITY CANCER THERAPY; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; PROGNOSIS; TREATMENT OUTCOME;

EID: 85037171336     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/CON.0000000000000554     Document Type: Review

References (55)

1. Ostrom QT Gittleman H Fulop J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol 2015; 17 (suppl 4): iv1-iv62. doi:10.1093/neuonc/nov189.
2. Louis DN Perry A Reifenberger G. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016; 131 (6): 803-820. doi:10.1007/s00401-016-1545-1.
3. Wen PY Huse JT. 2016 World Health Organization classification of central nervous system tumors. Continuum (Minneap Minn) 2017; 23 (6 Neuro-oncology): 1531-1547.
4. Ostrom QT Bauchet L Davis FG. The epidemiology of glioma in adults: A "state of the science" review. Neuro Oncol 2014; 16 (7): 896-913. doi:10.1093/neuonc/nou087.
5. Klein JP Dietrich J. Neuroradiologic pearls for neuro-oncology. Continuum (Minneap Minn) 2017; 23 (6 Neuro-oncology): 1619-1634.
6. Weller M Stupp R Hegi ME. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol 2012; 14 (suppl 4): iv100-iv108. doi:10.1093/neuonc/nos206.
7. Esteller M Garcia-Foncillas J Andion E. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343 (19): 1350-1354. doi:10.1056/NEJM200011093431901.
8. Stupp R Mason WP van den Bent MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10): 987-996. doi:10.1056/NEJMoa043330.
9. Hegi ME Diserens AC Gorlia T. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352 (10): 997-1003. doi:10.1056/NEJMoa043331.
10. Gilbert MR Wang M Aldape KD. Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. J Clin Oncol 2013; 31 (32): 4085-4091. doi:10.1200/JCO.2013.49.6968.
11. Wick W Hartmann C Engel C. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27 (35): 5874-5880. doi:10.1200/JCO.2009.23.6497.
12. Wick W Platten M Meisner C. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13 (7): 707-715. doi:10.1016/S1470-2045(12)70164-X.
13. Malmström A Grønberg BH Marosi C. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13 (9): 916-926. doi:10.1016/S1470-2045(12)70265-6.
14. Perry JR Laperriere N O'Callaghan CJ. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). J Clin Oncol 2016; 34 (18): Abstract. doi:10.1200/JCO.2016.34.18-suppl.LBA2.
15. van den Bent MJ Erdem-Eraslan L Idbaih A. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic oligodendrogliomas and oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res 2013; 19 (19): 5513-5522. doi:10.1158/1078-0432.CCR-13-1157.
16. Dubbink HJ Atmodimedjo PN Kros JM. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: A report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol 2016; 18 (3): 388-400. doi:10.1093/neuonc/nov182.
17. Wick W Meisner C Hentschel B. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013; 81 (17): 1515-1522. doi:10.1212/WNL.0b013e3182a95680.
18. Yan H Parsons DW Jin G. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360 (8): 765-773. doi:10.1056/NEJMoa0808710.
19. Nobusawa S Watanabe T Kleihues P Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009; 15 (19): 6002-6007. doi:10.1158/1078-0432.CCR-09-0715.
20. Gorlia T Delattre JY Brandes AA. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. Eur J Cancer 2013; 49 (16): 3477-3485. doi:10.1016/j.ejca.2013.06.039.
21. Lai A Kharbanda S Pope WB. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 2011; 29 (34): 4482-4490. doi:10.1200/JCO.2010.33.8715.
22. van den Bent MJ Brandes AA Taphoorn MJ. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-Term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31 (3): 344-350. doi:10.1200/JCO.2012.43.2229.
23. Cairncross G Wang M Shaw E. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-Term results of RTOG 9402. J Clin Oncol 2013; 31 (3): 337-343. doi:10.1200/JCO.2012.43.2674.
24. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455 (7216): 1061-1068. doi:10.1038/nature07385.
25. Verhaak RG Hoadley KA Purdom E. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17 (1): 98-110. doi:10.1016/j.ccr.2009.12.020.
26. Brennan CW Verhaak RG McKenna A. The somatic genomic landscape of glioblastoma. Cell 2013; 155 (2): 462-477. doi:10.1016/j.cell.2013.09.034.
27. Sanai N Polley MY McDermott MW. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011; 115 (1): 3-8. doi:10.3171/2011.2.JNS10998.
28. Oszvald A Güresir E Setzer M. Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg 2012; 116 (2): 357-364. doi:10.3171/2011.8.JNS102114.
29. Hervey-Jumper SL Berger MS. Role of surgical resection in low-and high-grade gliomas. Curr Treat Options Neurol 2014; 16 (4): 284. doi:10.1007/s11940-014-0284-7.
30. Bloch O Han SJ Cha S. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg 2012; 117 (6): 1032-1038. doi:10.3171/2012.9.JNS12504.
31. Walker MD Green SB Byar DP. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303 (23): 1323-1329. doi:10.1056/NEJM198012043032303.
32. Stupp R Hegi ME Mason WP. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10 (5): 459-466. doi:10.1016/S1470-2045(09)70025-7.
33. Brada M Stenning S Gabe R. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 2010; 28 (30): 4601-4608. doi:10.1200/JCO.2009.27.1932.
34. Roa W Brasher PM Bauman G. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial. J Clin Oncol 2004; 22 (9): 1583-1588. doi:10.1200/JCO.2004.06.082.
35. Wick W Roth P Hartmann C. Long-Term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol 2016; 18 (11): 1529-1537. doi:10.1093/neuonc/now133.
36. Lassman AB Iwamoto FM Cloughesy TF. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol 2011; 13 (6): 649-659. doi:10.1093/neuonc/nor040.
37. Clinicaltrials.gov website Radiation therapy with concomitant and adjuvant temozolomide versus radiation therapy with adjuvant PCV chemotherapy in patients with anaplastic glioma or low grade glioma (NCT00887146). clinicaltrials.gov/ct2/show/NCT00887146. Updated August 16, 2017. Accessed October 4, 2017.
38. van den Bent M Erridge S Vogelbaum MA. Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial. J Clin Oncol 2016; 34 (18): Abstract. doi:10.1200/JCO.2016.34.18-suppl.LBA2000.
39. Friedman HS Prados MD Wen PY. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27 (28): 4733-4740. doi:10.1200/JCO.2008.19.8721.
40. Kreisl TN Kim L Moore K. Phase II trial of single-Agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27 (5): 740-745. doi:10.1200/JCO.2008.16.3055.
41. Cohen MH Shen YL Keegan P Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009; 14 (11): 1131-1138. doi:10.1634/theoncologist.2009-0121.
42. Gilbert MR Dignam JJ Armstrong TS. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370 (8): 699-708. doi:10.1056/NEJMoa1308573.
43. Chinot OL Wick W Mason W. Bevacizumab plus radiotherapy-Temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370 (8): 709-722. doi:10.1056/NEJMoa1308345.
44. Taal W Oosterkamp HM Walenkamp AM. Single-Agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial. Lancet Oncol 2014; 15 (9): 943-953. doi:10.1016/S1470-2045(14)70314-6.
45. Wick W Brandes AA Gorlia T. EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. J Clin Oncol 2016; 34 (15): Abstract. doi:10.1200/JCO.2016.34.15-suppl.2001.
46. Stupp R Wong ET Kanner AA. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. Eur J Cancer 2012; 48 (14): 2192-2202. doi:10.1016/j.ejca.2012.04.011.
47. Stupp R Taillibert S Kanner AA. Maintenance therapy with tumor-Treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial. JAMA 2015; 314 (23): 2535-2543. doi:10.1001/jama.2015.16669.
48. Macdonald DR Cascino TL Schold SC Jr Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8 (7): 1277-1280. doi:10.1200/JCO.1990.8.7.1277.
49. Wen PY Macdonald DR Reardon DA. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol 2010; 28 (11): 1963-1972. doi:10.1200/JCO.2009.26.3541.
50. Nayak L DeAngelis LM Brandes AA. The Neurologic Assessment in Neuro-Oncology (NANO) scale: A tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol 2017; 19 (5): 625-635. doi:10.1093/neuonc/nox029.
51. Brown CE Alizadeh D Starr R. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 2016; 375 (26): 2561-2569. doi:10.1056/NEJMoa1610497.
52. Neagu MR Reardon DA. An update on the role of immunotherapy and vaccine strategies for primary brain tumors. Curr Treat Options Oncol 2015; 16 (11): 54. doi:10.1007/s11864-015-0371-3.
53. Reardon D Schuster J Tran DD. ReACT: overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. J Clin Oncol 2015; 33 (15): Abstract. doi:10.1200/jco.2015.33.15-suppl.2009.
54. Weller M Butowski N Tran DD. ATIM-03. ACT IV: An international, double-blind, phase III trial of rindopepimut in newly diagnosed, EGFRvIII-expressing glioblastoma. Neuro Oncol 2016; 18 (suppl 6): vi17-vi18. doi:10.1093/neuonc/now212.068.d
55. Wen PY Reardon D Phuphanich S. A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients. J Clin Oncol 2014; 32: Abstract. doi:10.1200/jco.2014.32.15-suppl.2005.